GlassScriptPhysician profile
Thomas Poole Phillips
NPI 1508150830
$2,016.07
in general payments reported to CMS, 2019-2025
24 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what 92% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $283 · 2024: $355 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $381.70 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Teva Pharmaceuticals USA, INC. | $206.93 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $170.29 | 2023-2025 | Caplyta |
| Abbvie INC. | $162.86 | 2023-2025 | |
| Amgen INC. | $154.34 | 2024-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $137.88 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $132.61 | 2023-2025 | Rexulti |
| Dexcom, INC. | $115.25 | 2024-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $64.04 | 2023-2025 | Gemtesa |
| Pfizer INC. | $57.41 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $57.04 | 2025 | |
| Exact Sciences Corporation | $56.09 | 2023-2024 | Cologuard Collection Kit |
| Baxter Healthcare | $42.46 | 2025 | Hillrom - Vest System Model 205 Acute Care |
| Viatris Specialty LLC | $39.24 | 2025 | Yupelri |
| Astellas Pharma US INC | $32.85 | 2025 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.55 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $29.93 | 2024-2025 | Airsupra |
| Novo Nordisk INC | $29.30 | 2024-2025 | Ozempic, Rybelsus |
| Tactile Systems Technology INC | $23.94 | 2025 | Nimbl, Flexitouch Plus |
| Hologic Sales and Service, LLC | $23.36 | 2025 | Thinprep 2000 Processor, Aptima |
| Vertex Pharmaceuticals Incorporated | $20.81 | 2025 | |
| Vanda Pharmaceuticals INC. | $20.25 | 2025 | Fanapt |
| Mylan Specialty L.P. | $13.85 | 2023 | Yupelri |
| Phathom Pharmaceuticals, INC. | $13.09 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.